Literature DB >> 6211979

Combination therapy for evolving myocardial infarction: intracoronary thrombolysis and percutaneous transluminal angioplasty.

S Goldberg, P L Urban, A Greenspon, M Lebenthal, P Walinsky, P Maroko.   

Abstract

Nonsurgical coronary reperfusion for evolving myocardial infarction is a promising new technique for the salvage of jeopardized myocardium. Successful reperfusion can be established by intracoronary infusion of streptokinase in approximately 75 percent of patients within the first 6 hours of transmural infarction [1.2]. Following recanalization, most patients are left with high grade fixed coronary stenoses which are potential sites for recurrent thrombus formation. Since the underlying site for coronary thrombosis is still present, reocclusion may occur. Indeed, early experience suggests that recurrence of thrombosis is not uncommon [3.4]. Therapy for evolving myocardial infarction should, in some patients, involve not only thrombolysis, but also an attack on the fixed coronary lesion. We describe a patient wit evolving myocardial infarction who was treated successfully with combination therapy consisting of intracoronary streptokinase followed by percutaneous transluminal coronary angioplasty [5].

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6211979     DOI: 10.1016/0002-9343(82)90861-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

Review 1.  Thrombolytic therapy in acute myocardial infarction. A perspective.

Authors:  S Sherry
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Intracoronary thrombolysis in evolving myocardial infarction. Sequential angiographic analysis of left ventricular performance.

Authors:  A Cribier; J Berland; O Champoud; N Moore; P Behar; B Letac
Journal:  Br Heart J       Date:  1983-11

Review 3.  Coronary thrombolysis for evolving myocardial infarction.

Authors:  J F Spann; S Sherry
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.